Growth Hormone (GH), or somatotropin, is the protein hormone secreted by the anterior pituitary that dynamically coordinates somatic growth, skeletal maturation and metabolic adaptation. Within the architecture of the hypothalamic-pituitary-peripheral axis, GH represents an endocrine signal with an important conceptual peculiarity: it combines an indirect trophic component mediated by the induction of insulin-like growth factor 1 (IGF-1), mainly hepatic, with a direct component on target tissues, especially evident in lipid, carbohydrate and protein metabolism. This dual nature makes GH one of the best examples of endocrine control in which the final effect does not depend only on the circulating concentration of the hormone, but on the relationship between secretory pattern, receptor availability, production of peripheral mediators and integration with nutritional and circadian status.
In physiology, GH cannot be understood as a stable signal or a “fixed-value” variable. Its secretion is strongly pulsatile, with peaks of variable amplitude and intervals of relative quiescence, and its overall bioaction emerges from the temporal integration of these oscillations with the pharmacokinetics of the molecule and with the peripheral response, particularly the generation of IGF-1 and the modulation of IGF-binding proteins. This leads to a central principle: somatotropic function cannot be described by a single number, but by a dynamic balance between pituitary pulses, tissue “reading” of the signal and multiple feedback loops that regulate both the quantity and quality of endocrine output.
GH belongs to the category of “effector” pituitary hormones with widespread systemic actions, and it differs from classical tropic hormones because it does not simply stimulate a single target gland, but exerts pleiotropic modulation across multiple organs. Its endocrinological function emerges from the interaction of two complementary physiological arms. On one hand, GH induces the synthesis and secretion of IGF-1 and other related molecules, including local mediators, that support linear growth, tissue anabolism and skeletal maturation. On the other hand, GH acts directly on the liver, muscle, adipose tissue, bone and other compartments, orienting energy homeostasis toward a “glucose-sparing” state and substrate availability, mainly through increased lipolysis and reduced peripheral glucose utilization in selected conditions.
Integration with the hypothalamus is the core of regulation. GH is a paradigmatic example of an axis in which pituitary output is governed by the balance between central stimulatory and inhibitory signals: the excitatory drive mediated by hypothalamic pro-secretory signals, with a primary role for growth hormone-releasing hormone (GHRH) and a contribution from secretagogues such as ghrelin, and inhibition mediated by somatostatin, which organizes temporal windows of permissiveness and phases of suppression. In this context, the pituitary is not a passive transducer, but a node of biological integration in which metabolic, circadian and neurovegetative signals converge and are translated into pulsatile secretion whose amplitude and frequency change coherently with age, sex, body composition, nutritional status and sleep.
The pulsatile nature of GH has profound endocrine implications. In a pulsatile system, biological information does not reside only in the total amount secreted, but in the dynamics of the signal: peaks, duration, intervals, irregularity and tissue response over time. This principle explains why the same “mean exposure” may produce different effects if obtained through physiological peaks rather than through a flatter profile. In addition, some aspects of the peripheral response, including hepatic gene induction of IGF-1 and the modulation of metabolic enzymes and transporters, are sensitive to the timing of receptor activation and to recovery windows of intracellular signaling. GH physiology is therefore, strictly speaking, a physiology of time.
A second key element is the distinction between endocrine action and local action. Although circulating IGF-1 is an essential mediator of many growth-related functions, a relevant proportion of “tissue” effects depends on local production of IGF-1 and other GH-induced mediators through paracrine and autocrine mechanisms. This organization allows fine regulation: the systemic signal sets a general direction, but the final response is calibrated locally according to nutrient availability, mechanical load, inflammation, concomitant hormonal status, such as insulin, thyroid hormones, sex steroids and glucocorticoids, and tissue maturation. In practice, GH provides an “anabolic permission” that each tissue interprets according to its own biological context.
The feedback system is multilayered and ensures stability without losing adaptability. IGF-1 exerts negative feedback on the axis by reducing pituitary secretion and modulating hypothalamic circuits, while GH itself can contribute to short feedback loops and to the remodeling of central sensitivity. Stability, however, does not mean fixity: the somatotropic axis modifies set point and gain in response to physiological signals. Fasting, for example, tends to increase GH secretion while reducing IGF-1, creating an energy-mobilizing state in which the hormone promotes substrate availability while growth is “paused”. Conversely, when energy and insulin availability are adequate, hepatic transduction of the somatotropic signal and IGF-1 production become more efficient, supporting anabolic and growth functions.
The interaction with sleep and the biological clock represents an additional structural level of regulation. GH shows a strong relationship with sleep quality and architecture, with peaks typically associated with deep sleep phases, and marked variability in relation to sleep deprivation, shift work and circadian desynchronization. Circadian regulation should not be understood as a simple accessory oscillation, but as a way to couple growth and tissue repair to biologically favorable time windows, reducing conflicts with acute daytime energy demands and optimizing the efficiency of anabolism.
A final relevant endocrinological aspect is that GH activity depends not only on secretion, but also on the peripheral “readability” of the signal. The presence of growth hormone-binding protein in the circulation, derived from the receptor and able to bind a proportion of plasma GH, modifies distribution, half-life and tissue availability of the hormone, acting as a kinetic regulator and, in part, as a buffer against rapid variations. In parallel, receptor density and sensitivity in target tissues, together with the competence of the transduction pathway, with a crucial role for the Janus kinase 2-signal transducer and activator of transcription (JAK2-STAT) cascade, determine whether a secretory peak is translated into a robust or attenuated biological output. GH physiology is therefore a two-component system: pituitary emission and peripheral interpretation.
In summary, the somatotropic axis is not a simple “stimulus-response” circuit, but an integrated control system in which the hormone operates as a temporal, metabolic and plastic signal. Growth and energy homeostasis emerge from the balance between pituitary pulses, IGF-1 production, local modulations and central feedback, with continuous adaptation to the organism’s needs under different physiological conditions.
Human GH is a protein hormone belonging to the somatomammotropin family and represents a particularly instructive model of how molecular microheterogeneity and secretory regulation converge in determining bioactivity and analytical measurability. The predominant “classical” circulating form is the so-called 22 kDa GH, a single-chain protein composed of 191 amino acids, organized in a typical four-alpha-helix bundle fold that characterizes numerous cytokines and related hormones. This architecture is not an abstract structural detail: it defines interaction surfaces required for binding to the GH receptor and for the formation of the active complex capable of initiating signal transduction.
From a genetic standpoint, pituitary GH derives mainly from expression of the GH1 gene, located within a gene cluster that also includes genes expressed in the placenta, such as GH2, and genes encoding related hormones. Biosynthesis begins as a longer precursor: the GH1 transcript encodes a 217-amino acid pre-protein that includes an N-terminal signal peptide required for entry into the secretory compartment. Maturation involves signal peptide removal and generation of the mature 191-amino acid GH, which is folded, stabilized and targeted to secretory granules. This step clarifies a general principle of endocrine biology: for secreted hormones, the “active form” is the final product of a quality-control pathway that begins in the endoplasmic reticulum and culminates in regulated exocytosis.
The conformational stability of GH is supported by specific disulfide bonds. The 22 kDa form contains two intramolecular disulfide bonds, which help fix the geometry of the helices and preserve fold integrity in the extracellular environment. These structural constraints influence not only resistance to degradation, but also the exposure of regions involved in receptor binding. In other words, GH bioactivity depends on the molecule’s ability to maintain a conformation compatible with assembly of the GH-receptor complex, and correct oxidation of disulfide bonds is an integral part of this biological competence.
A core element of GH biochemistry is the presence of isoforms and proteoforms. The 22 kDa isoform is not the only circulating species: an important variant is 20 kDa GH, generated by alternative splicing of the GH1 transcript and characterized by the absence of a short internal segment of 15 amino acids. This apparently small difference produces measurable variations in biochemical and receptor-related properties, with potential consequences for pharmacokinetics, immunoreactivity and the ability to activate specific intracellular pathways in some models. In addition to these two main isoforms, minor forms, fragments and products of peripheral metabolism may be present and, although they have limited relevance as a primary physiological signal, they may influence analytical interpretation in selected contexts.
Variability from splicing is compounded by post-translational modifications, which further broaden the spectrum of proteoforms. Forms of GH have been described with modifications such as deamidation, N-terminal acylation, phosphorylation, acetylation, limited proteolysis, aggregation and glycosylation. In particular, glycosylated forms of GH exist, including O-glycosylated and N-glycosylated variants identified in pituitary extracts and proteomic analyses. In physiological terms, these proteoforms should not be interpreted as biochemical curiosities: they represent a possible mechanism through which the somatotroph cell modulates stability, distribution and immunological recognition of the molecule, especially in conditions in which secretory trafficking and the intracellular environment change. Glycosylation, when present, can alter charge, steric hindrance and interactions with plasma proteins, contributing to differences in clearance and, above all, to differences between bioactivity and immunoreactivity.
GH synthesis in somatotroph cells follows the classical pathway of secreted proteins, but with relevant quality-control aspects. After translation on ribosomes associated with the rough endoplasmic reticulum, the nascent chain enters the lumen, where folding and disulfide oxidation occur under the supervision of chaperones and quality-control systems. Misfolded molecules are retained and targeted for degradation, whereas correctly matured molecules proceed to the Golgi apparatus and are packaged into regulated secretory granules. The efficiency of this process influences the amount of hormone available for pulsatile release and, indirectly, the composition of secreted forms, since some proteoforms may be preferentially selected or discarded by the cellular quality-control system.
GH is released through regulated exocytosis in response to hypothalamic and peripheral signals that converge on intracellular second messengers, mainly calcium and cyclic adenosine monophosphate (cAMP), and on granule priming mechanisms. This organization explains why secretion is pulsatile: the somatotroph cell alternates phases of permissiveness and phases of suppression, and the availability of granules ready for release depends on the balance between synthesis, maturation, recycling and secretory stimulation. From a biochemical standpoint, this means that the composition of circulating GH at any given moment is the result of production, storage and release, not a simple snapshot of instantaneous synthesis.
An often underestimated component of the system biochemistry is the presence in plasma of growth hormone-binding protein (GHBP), which binds a variable proportion of circulating GH. GHBP derives from the GH receptor and can modify the pharmacokinetics of the hormone by prolonging its half-life and influencing distribution between free and bound compartments. Conceptually, GHBP introduces a level of “post-secretory” regulation: the same pituitary secretion can translate into different tissue exposures depending on binding capacity and dissociation dynamics. In addition, the presence of GHBP and other plasma proteins can influence some measurement methods, contributing to variability between analytical platforms.
The relationship between immunoreactivity and bioactivity is also central for GH. Immunoassays recognize epitopes that may be conformational and therefore sensitive to isoforms, proteoforms, fragments and aggregates. Some species may be detected with different efficiencies by different antibodies, generating inter-method discrepancies, particularly in conditions in which isoform distribution changes or high-molecular-weight forms are present. There are also conditions in which GH may form complexes with immunoglobulins or other proteins, with potential effects on clearance and laboratory results. This is not a technical detail: it makes clear that GH is a biological signal whose measurement depends on the molecular object actually recognized by the assay.
Another biochemical issue concerns the relationship between endogenous GH and recombinant GH. The therapeutic GH commonly used structurally corresponds to the main 22 kDa isoform, but the context of administration determines pharmacokinetics that are profoundly different from the physiological pulsatile pattern. This highlights a general principle: the molecule may be the same, but the timing of exposure, interaction with GHBP and the way in which the receptor is activated over time can differ substantially, with consequences for IGF-1 output, metabolic effects and individual variability of response. GH biochemistry, therefore, cannot be separated from kinetics, because structure and circulating fate cooperate in defining the final effect.
In summary, the molecular biology of GH cannot be reduced to a single “22 kDa protein”. The somatotropic signal emerges from a set of determinants: isoforms generated by splicing, post-translational proteoforms, conformational stability supported by disulfide bonds, regulation of secretory trafficking, complexation with GHBP and variability in recognition by immunoassays. Through these levels, the somatotroph cell controls not only how much GH is secreted, but also which set of molecular forms contributes to the circulating signal, making GH biochemistry an integral part of its physiology.
In light of this complexity, the molecular structure of GH can be understood only by simultaneously considering multiple organizational levels, from the gene to circulating proteoforms. The final endocrine behavior does not depend on a single determinant, but emerges from the integration of sequence, folding, post-translational modifications and kinetic fate of the molecule in plasma. Some elements, in particular, represent indispensable conceptual nodes for correctly interpreting both physiology and variability in laboratory results.
Conceptual nodes of GH biochemistry and molecular structure
Growth hormone (GH) secretion is intrinsically pulsatile and depends on a complex temporal architecture in which the concentration measured in a single sample is only the “snapshot” of a signal that changes rapidly over time. In healthy individuals, most GH is released in the form of secretory bursts separated by phases of low secretion, with a distribution that reflects the integration of hypothalamic regulation, sleep-wake status, acute metabolic demands and slower modulations related to age, sex and nutritional state. This release mode is not an accessory detail: pulsatility is a functional property that enables effective receptor-level signal peaks while preserving fine control of energy balance and anabolic processes without maintaining continuous tonic stimulation.
At the ultradian scale, GH peaks emerge from circuit dynamics that alternate stimulation and inhibition. Each secretory pulse represents the momentary result of a facilitation window, in which the somatotroph cell increases the probability of granule exocytosis, followed by a braking phase that restores a nadir. At the cellular level, the somatotroph integrates signals that converge on intracellular calcium, second messengers such as cAMP and regulatory kinases, determining granule trafficking, priming and membrane fusion through exocytosis protein complexes. Pulsatile secretion also implies that the secretory “reserve” and response capacity vary over time: the amplitude of a burst depends not only on the acute stimulus, but also on granule recharge status, receptor sensitivity and the inhibitory tone that precedes the event.
Over a 24-hour horizon, GH physiology shows a particularly close relationship with sleep. In healthy individuals, the most reproducible burst tends to appear shortly after sleep onset and is strongly associated with slow-wave sleep. This coupling does not mean that GH is simply a “sleep hormone”: it rather indicates that the network governing sleep architecture and the network governing the somatotropic axis share regulatory nodes and common temporal windows. Sleep quality, fragmentation and shifts in the sleep-wake rhythm can remodel burst distribution and the relationship between nocturnal peaks and daytime secretion, without necessarily corresponding to a stable change in somatotropic function. In parallel, daytime bursts linked to states of arousal, physical activity and metabolic stimuli exist, highlighting the short-term “reactive” nature of the axis.
The somatotropic axis is highly sensitive to acute metabolic status. GH tends to increase in conditions requiring substrate mobilization, such as exercise and some states of reduced energy availability, while it is attenuated by signals indicating abundance of immediately available fuel, particularly increased glycemia and insulin. This logic is consistent with the role of GH as a regulator of nutrient partitioning: in the short term, the signal promotes fatty acid availability and glucose sparing, while in the medium term it supports anabolic processes through the IGF cascade. The metabolic component interacts with the temporal component: for the same “stimulus”, the GH response depends on the circadian window, the sleep context and the status of hypothalamic inhibitory tone.
Slow modulations of GH secretion are marked and physiologically informative. During puberty, there is an increase in pulsatile secretory mass, linked to the interaction between neuroendocrine maturation and increased sex steroids, with differences between males and females in burst distribution and amplitude. With advancing age, there is a progressive reduction in somatotropic output, involving both burst amplitude and effective frequency, in association with changes in slow-wave sleep, body composition and sensitivity to regulatory signals. Chronic nutritional status and body composition also influence the signal: GH secretion is not a single “value”, but a network variable that reflects the balance between energy status, sleep and hypothalamic-pituitary integration.
Hypothalamic regulation of GH is one of the most instructive models of neuroendocrine control, because it is based on the antagonistic cooperation of two main signals, one stimulatory and one inhibitory, whose temporal alternation generates the pulsatility of pituitary output. The stimulatory signal is GHRH, produced by hypothalamic neurons projecting to the median eminence; the inhibitory signal is somatostatin, released by hypothalamic circuits that exert a powerful brake on the somatotroph. GH therefore does not emerge from a single “switch”, but from a circuit dynamic in which the secretion window typically opens when stimulation increases and, above all, when the brake is transiently reduced, allowing the burst to be expressed.
Anatomically and functionally, the median eminence and the hypothalamic-pituitary portal system constitute the channel through which hypothalamic signals become peripheral endocrine regulation. In this microenvironment, axon terminals, the portal vascular network and specialized glial components cooperate in defining the effective availability of secretagogues for pituitary cells. Signal transmission is not only “amount released”, but also accessibility, local degradation, perivascular diffusion and temporal synchronization of inputs. This organization allows the hypothalamus to transform rapid neural information into an endocrine output that, although pulsatile, is coherent and reproducible over hours and days.
GHRH acts on somatotrophs through specific receptors and activates second-messenger pathways that increase GH synthesis and release, enhancing the probability of exocytosis and sustaining secretory capacity over time. Somatostatin, by contrast, reduces the functional excitability of the somatotroph and lowers the probability of granule fusion, imposing a “threshold” that must be overcome for a burst to occur. In this framework, pulsatility does not necessarily require large oscillations of stimulation: it may also be generated by relatively modest oscillations in stimulation if associated with effective oscillations of the brake. The window of somatostatinergic withdrawal is therefore a key concept for understanding why some physiological stimuli produce clear peaks at specific times and are far less effective at others.
Alongside the GHRH-somatostatin pair, a third signal with a crucial physiological role is ghrelin and, more broadly, the pathway of growth hormone secretagogues through the growth hormone secretagogue (GHS) receptor. Ghrelin, produced mainly in the stomach and also active centrally, directly links nutritional status, meal anticipation and the somatotropic axis. Its role is not redundant with that of GHRH: it can amplify the somatotropic response, modulate burst synchronization and interact with hypothalamic circuits that regulate appetite and energy balance. This integration explains why the somatotropic axis is sensitive not only to “how much” food is consumed, but also to the timing of hunger-satiety signals and to the neurobehavioral context.
The hypothalamic network controlling GH is deeply interwoven with metabolic and circadian circuits. Inputs from leptin, insulin and arcuate nucleus signals connect energy availability and GH secretion; circuits of the central clock and sleep architecture organize temporal windows in which the balance between GHRH and somatostatin favors the emergence of nocturnal bursts associated with slow-wave sleep. Monoaminergic and cholinergic systems, together with stress mediators, also modulate the circuit’s excitability set, helping to make GH output a true “network output” that incorporates information on sleep, nutrition, physical activity and the organism’s adaptive status.
Peripheral feedback of the somatotropic axis gives the system the ability to maintain functional stability despite variable stimuli and pulsatile output. The core principle is that GH stimulates the production of IGF-1 and other mediators at hepatic and peripheral levels, and that IGF-1, together with GH itself, acts as a return signal to modulate hypothalamic and pituitary activity. This feedback operates on several levels: it reduces secretory drive when overall exposure to the somatotropic signal is high and allows an increase when exposure is low, maintaining the axis in a dynamic equilibrium. The important conceptual point is that feedback does not “flatten” pulsatility, but governs its amplitude, temporal distribution and the circuit’s ability to generate effective bursts.
At the pituitary level, IGF-1 can modulate GH synthesis and secretion and influence somatotroph sensitivity to hypothalamic inputs. At the hypothalamic level, IGF-1 and GH help remodel the balance between stimulatory and inhibitory signals, favoring a state in which GHRH drive is contained and the somatostatinergic brake becomes relatively more efficient when the axis is “saturated”. This multilayered logic is essential for understanding why the relationship between GH and IGF-1 is not a simple proportionality in the short term: GH oscillates over minutes and hours, whereas IGF-1 integrates exposure over longer time scales and reflects the sum of secretory effects and peripheral sensitivity.
The concept of an individual set point in the GH-IGF axis derives from the fact that each subject tends to maintain a relatively stable relationship between pulsatile GH output, IGF-1 production and the response of target tissues. This set point is determined by deep biological variables: genetics of receptors and signaling pathways, efficiency of hepatic IGF-1 production, availability of binding proteins such as IGFBP-3 and of the complex with the acid-labile subunit, insulin and nutritional status, levels of thyroid hormones and sex steroids, as well as factors related to sleep and body composition. As a result, there is broad interindividual variability even in healthy populations, whereas intraindividual variability, if correctly measured over time, tends to be more limited because the circuit maintains a relatively constant personal equilibrium.
Feedback of the somatotropic axis is also temporal. A relatively rapid component modulates burst probability and response to acute stimuli, while a slower component acts on gene transcription, secretory capacity and tissue sensitivity, stabilizing the axis over days and weeks. This dual level explains why transient changes in sleep or metabolic status may modify burst distribution without persistently shifting the set point, and why, conversely, chronic changes in nutritional status or hormonal profile may recalibrate the circuit in a more lasting way. The notion of set point is therefore the conceptual key for interpreting the axis as an adaptive system, in which GH is the rapid and pulsatile signal and IGF-1 represents a slower integrator of overall somatotropic exposure.
A further element of system robustness is that the somatotropic signal is distributed across several compartments: circulating GH, protein-bound fraction, receptor dynamics and peripheral IGF production, each with its own time constants. This stratification prevents small GH fluctuations from automatically translating into large effector variations, but allows the system to be highly reactive when the context requires it. In physiology, therefore, feedback and set point are not abstract concepts: they describe the way in which a pulsatile axis remains stable, informative and adaptable, preserving coherence between brain, pituitary and periphery.
The GH receptor (GHR) belongs to the class I cytokine receptor family and is designed to transform a pulsatile endocrine signal into long-lasting transcriptional and metabolic programs. Unlike G protein-coupled receptors (GPCRs), GHR does not possess a seven-transmembrane-helix domain or intrinsic enzymatic activity; its signaling logic is based on an extracellular domain responsible for hormone recognition, a single transmembrane passage and a cytoplasmic tail that acts as an assembly platform for kinases and adaptors. Structurally, the extracellular domain is organized into modules typical of cytokine receptors and allows highly specific interaction with GH in such a way that a binding event is converted into a geometric rearrangement of the receptor complex. A key concept is that GHR tends to exist as a preformed oligomeric complex, or at least one predisposed to association, and that the hormone mainly acts as an element that stabilizes an active configuration, favoring a conformational change and a rotation or repositioning of the intracellular regions capable of activating associated kinases.
GHR is expressed in many tissues, and its distribution explains the dual nature of GH action: on one hand, a systemic endocrine effect; on the other, tissue-specific control that depends on receptor density, availability of intracellular cofactors and integration with nutritional and inflammatory signals. The liver is a central node because activation of hepatic GHR supports endocrine production of IGF-1, but the receptor is also functional in bone, cartilage, muscle, adipose tissue, kidney, heart and immune systems, where signal output may differ profoundly despite starting from the same ligand. This variability is not an exception, but the rule of GH physiology: the receptor acts as a modulable switch that generates different responses depending on metabolic context, age and inflammatory status.
GHR activation predominantly recruits and activates JAK2, a cytosolic tyrosine kinase that constitutively associates with the intracellular portion of the receptor. When the hormone induces the active configuration, JAK2 undergoes trans-autophosphorylation, phosphorylates tyrosine residues of the receptor and creates docking sites for proteins containing Src homology 2 (SH2) domains. The most representative module is the JAK2-STAT axis, in which STAT proteins, especially STAT5, are recruited, phosphorylated, dimerize and translocate to the nucleus, where they control transcription of genes mediating somatic growth, differentiation and metabolism. In the liver, this transcriptional program includes regulation of the IGF axis and IGF-binding proteins, with endocrine consequences that amplify and stabilize GH action over time. Transduction, however, cannot be reduced to a single track, because STAT signaling coexists with pathways that control proliferation, survival and metabolism in faster and often more tissue-specific ways.
Alongside the STAT arm, GHR activates integration pathways that include mitogen-activated protein kinases (MAP kinases) and phosphoinositide 3-kinase-protein kinase B (PI3K-AKT). Through adaptors such as SHC, GRB2 and the RAS-RAF axis, the signal may converge on extracellular signal-regulated kinase (ERK) with effects on growth and cellular remodeling, whereas activation of PI3K and AKT interacts with metabolic programs and with the control of protein synthesis and survival. In many tissues, GH signaling also intersects with circuits regulating insulin action and energy balance, generating an output that may be anabolic in muscle and skeleton while at the same time lipolytic and potentially antagonistic to insulin in some compartments under specific conditions. This network architecture explains why the same hormone can promote linear growth during development, maintenance of lean mass in adulthood and remodeling of body composition, while exerting complex effects on insulin sensitivity that depend on dose, timing and nutritional status.
The GHR response is subject to tight dynamic regulation, necessary because GH is physiologically pulsatile and because the organism must prevent excess signaling in case of prolonged stimulation. A fundamental component is the production of intracellular inhibitors such as SOCS, induced by the JAK-STAT axis itself and capable of attenuating the response by interfering with JAK2 and docking sites. In parallel, the receptor complex undergoes internalization and endosomal trafficking, with recycling or degradation depending on the context. Ubiquitination mechanisms and proteostatic control help determine signal duration and cellular sensitivity to the subsequent hormonal pulse, transforming endocrine pulsatility into a sequence of windows of competence followed by refractory phases that preserve the informational fidelity of the system.
A distinctive feature of GHR is the possibility of generating GH binding protein (GHBP), corresponding to the extracellular portion of the receptor present in the circulation. GHBP derives largely from proteolysis of GHR mediated by membrane metalloproteases, particularly systems attributable to ADAM17, and its generation is not a simple by-product, but an element that can modulate GH bioavailability, distribution kinetics and interpretation of hormone levels. Receptor cleavage also represents a way to rapidly reduce GH sensitivity in response to specific cellular stimuli, because loss of the extracellular portion and remodeling of the residual receptor attenuate the ability to activate JAK2. From this perspective, GHR should not be considered a static receptor, but a regulated entity whose density, structural integrity and trafficking directly contribute to somatotropic axis physiology.
Finally, GH signaling is strongly context-dependent because GHR communicates with receptors for growth factors, nutrient-sensitive pathways and inflammatory mediators. The presence of insulin, IGF-1, cytokines and signals derived from adipose tissue can amplify or attenuate specific branches of the response, modifying the relationship between the anabolic component and the lipolytic component and helping determine interindividual variability. For this reason, GHR should be interpreted as a network node that produces an integrated output, where the same GH pulse may have different effects if it occurs during fasting, after exercise, during deep sleep or under conditions of systemic inflammation.
The biological effects of GH are organized as an integrated program combining direct actions, mediated by GHR in target tissues, and indirect actions conveyed by the IGF-1 axis. This dual architecture allows GH to play a unique role: promoting growth and tissue remodeling in the long term, while also coordinating, in the short term, the allocation of energy substrates between storage and mobilization. Functionally, GH is not only a hormone of linear growth, but a regulator of body composition and metabolic adaptation, capable of modulating lean mass, adipose mass, protein turnover and responses to fasting and stress.
In the liver, GHR activation supports the production of IGF-1 and IGF-binding proteins, helping stabilize the growth signal and distribute it to peripheral tissues in a controlled way. IGF-1 acts as an endocrine and paracrine mediator, promoting anabolic processes in bone and muscle and participating in negative feedback on the hypothalamic-pituitary axis. This GH-IGF relationship is not linear in every condition, because hepatic IGF-1 production also depends on nutritional status, insulin and hepatic integrity, which explains why in some situations GH may be elevated without IGF-1 increasing proportionally, reflecting physiological modulation of signal transduction and hepatic synthesis.
At the skeletal level, GH contributes to longitudinal growth during development by stimulating growth-plate cartilage metabolism and osteoblastic function, with a close interaction between direct action and IGF mediation. Linear growth requires chondrocyte proliferation and differentiation, matrix expansion and subsequent ossification, and GH acts along this continuum by favoring an anabolic environment and coordinated turnover. In adults, the GH-IGF axis contributes to the maintenance of bone mass and remodeling, influencing the balance between formation and resorption and contributing to bone-tissue quality through effects on osteoblasts and the microenvironment. The physiological result is regulation of skeletal strength integrated with mechanical load, vitamin status and gonadal signals.
In skeletal muscle, GH supports preservation of lean mass and protein turnover, both through IGF-1 and through direct effects that modulate protein synthesis and substrate utilization. The overall effect tends to favor an anabolic state, especially in conditions in which the organism must preserve function and strength, but the intensity and net direction depend on protein intake, exercise and insulin status. In parallel, GH promotes the use of lipids as fuel, reducing relative dependence on glucose in some contexts and contributing to an energy-adaptation profile that becomes particularly evident during fasting or caloric restriction.
In adipose tissue, one of the most characteristic effects of GH is stimulation of lipolysis, with increased release of free fatty acids and glycerol and a tendency toward long-term reduction in body fat. This action is crucial for mobilizing energy when the organism must support high-demand functions without compromising glucose homeostasis. However, increased circulating fatty acids and modulation of intracellular pathways can also interfere with insulin action in some compartments, contributing to a dose- and context-dependent profile of insulin resistance. In physiology, this should not be read as a pathological effect, but as a substrate-partitioning strategy in which GH favors lipid use and preserves glucose for obligate tissues and for specific requirements of the nervous system.
In carbohydrate and hepatic metabolism, GH acts as a complex regulator that integrates glucose production and utilization with lipid availability and insulin action. In acute conditions or in specific physiological windows, GH can increase hepatic glucose production and reduce peripheral insulin sensitivity, whereas in the long term, through reduction of adipose mass and improvement of body composition, it may contribute to a different overall metabolic state. The distinction between acute and chronic effects is fundamental: the somatotropic axis does not operate as a single metabolic command, but as a temporal modulator that alternates phases of energy mobilization with phases of reconstruction and growth, with a balance that depends on the pulsatile pattern and on the interaction with sleep, nutrition and exercise.
GH also influences hydroelectrolyte balance and renal function, with a tendency toward sodium and water retention and modulation of some tubular transport processes, effects that integrate with hemodynamics and the overall hormonal state. These actions contribute to physiological variations in volemia and may participate in adaptation to exercise and growth, providing support for perfusion and substrate transport to remodeling tissues. In parallel, GH may modulate cardiovascular parameters and endothelial function indirectly through body composition, IGF-1 and metabolic control, maintaining coherence between tissue growth, perfusion demand and transport capacity.
Finally, GH exerts effects on immune systems and on tissues not classically considered endocrine, consistent with the fact that GHR is expressed in many cell populations. The GH-IGF axis participates in the control of cell growth, survival and stress response, with an impact that depends on the microenvironment and the presence of inflammatory signals. In physiology, this broad action should be understood as a component of the homeostatic function of the somatotropic axis, which coordinates growth and tissue repair with energy availability and systemic status.
GH physiology is an emblematic example of information encoded in time: measurement of a single plasma value does not represent a “stable concentration”, but a snapshot of a pulsatile signal with large ultradian oscillations and marked circadian modulation linked to sleep. GH secretion occurs in discrete pulses separated by intervals of low secretion, and the amplitude of these pulses, more than their simple frequency, determines much of the overall biological exposure. This architecture allows a strong receptor signal to be obtained during specific temporal windows, while avoiding continuous stimulation that could induce receptor desensitization and loss of system effectiveness.
The most reproducible determinant of GH rhythm in adults is sleep, with a large peak typically observed shortly after sleep onset and preferentially associated with the first phases of slow-wave sleep. This link is not a simple correlate, but reflects integration between the central circadian clock, hypothalamic tone of GHRH and somatostatin, autonomic modulation and metabolic signals. Sleep quality, continuity and stage architecture influence the amplitude and timing of pulses, and sleep fragmentation or sleep deprivation can reduce the nocturnal peak and redistribute secretion into less effective pulses. As a result, the same person may show very different profiles on different days while remaining in a physiological state, because the system responds sensitively to behavioral context.
At the ultradian scale, GH is characterized by pulses that may vary widely in amplitude and duration, and intraindividual variability is an integral part of physiology. The biological meaning of this pulsatility is twofold: on one hand, to maximize GHR activation during pulses; on the other, to allow recovery phases that preserve receptor sensitivity and transduction fidelity. IGF-1 also contributes to system stability, because it integrates GH action over time and provides a more continuous feedback signal, attenuating fluctuations and transforming a pulsatile input into a more stable endocrine output for peripheral tissues. In this sense, GH and IGF-1 are complementary: the former is a dynamic signal with high variability, the latter is a more integrated indicator of overall somatotropic exposure.
GH secretion is also deeply influenced by nutritional and metabolic signals. Fasting tends to favor an increase in GH, consistent with the need to mobilize lipid substrates and preserve glucose, whereas hyperglycemia and increased energy availability may reduce secretion. Free fatty acids, insulin and signals from adipose tissue help modulate the axis, explaining why increased adiposity and specific metabolic conditions are associated with reduced pulsatile amplitude and lower overall secretion even in the absence of a lesion of the hypothalamic-pituitary axis. Physical exercise represents a powerful physiological stimulus capable of transiently increasing GH secretion, with an effect that depends on intensity, duration, training status and carbohydrate availability, and that integrates with catecholamines and lactate as signals of energy demand.
GH variability is also marked between individuals and between sexes, because the somatotropic axis interacts with gonadal hormones and pubertal development. During puberty, relevant changes in secretion are observed, with increased overall output and changes in the pulsatile pattern, consistent with the requirements of growth and maturation. With aging, secretion tends to progressively decline, in parallel with changes in slow-wave sleep and body composition, and this reduction should be understood as part of life physiology rather than as an automatic indicator of disease. Acute stress may also modulate secretion, integrating the somatotropic axis with neuroendocrine and autonomic responses in order to coordinate energy availability and adaptive demands.
Overall, GH chronobiology imposes a fundamental interpretive principle: physiology cannot be described by a single isolated value, because the signal is dominated by pulsatility and sleep gating. Understanding physiological variability therefore requires considering timing, sleep architecture, nutritional status and physical activity as primary determinants of the secretory profile. This view makes the large variability observed between closely spaced measurements coherent and explains why the somatotropic axis uses time as a language, transforming behavioral and metabolic events into endocrine pulses capable of guiding growth, remodeling and energy adaptation.
The physiology of GH (growth hormone) changes profoundly throughout life because the somatotropic system must adapt to different biological needs: statural growth and tissue maturation during development, coordination between metabolism and body composition in adulthood, and homeostatic remodeling in older age. Unlike other endocrine axes, GH is a paradigmatic example of a hormone in which pulsatility and context dependence are integral parts of biological information: the same “mean concentration” may derive from very different secretory profiles, with different consequences for receptor signaling and peripheral response.
During fetal life and the transition to extrauterine life, GH secretion is high and relatively frequent. In the newborn, especially in the first weeks, basal levels can be much higher than in later pediatric age, and secretion shows broad episodes distributed across the 24 hours. In this phase, GH is not only a “growth hormone” in the strict sense, but contributes to the stabilization of energy homeostasis, supporting substrate availability through lipolytic actions and modulation of glucose utilization in an organism that rapidly shifts from continuous placental nutrition to intermittent feeding. From a developmental standpoint, tissue sensitivity to the somatotropic signal and the ability to transduce the stimulus into IGF-1 production are not yet equivalent to those of later life, making the axis more “shifted” toward adaptive dynamics and less constrained by a stable set point.
During childhood, the somatotropic system tends to organize into a more recognizable pattern, in which pulsatile secretion remains present but with lower mean levels than in the neonatal period. Under physiological conditions, information is mainly encoded in the temporal distribution of secretory bursts, with a relevant contribution from sleep and increasingly close integration with nutritional status. In parallel, the relationship between GH, IGF-1 and IGF-binding proteins becomes more coherent and reproducible, allowing more stable regulation of linear growth and maturation of muscle, bone and connective tissues. In this phase, feedback exerted by peripheral mediators and metabolic signals also helps progressively “fix” the individual characteristics of secretion, while wide margins of variability between healthy subjects remain.
During adolescence and puberty, the somatotropic axis enters its phase of maximal physiological activation. Pulsatile secretion increases markedly, with an overall increase that can reach approximately threefold compared with prepubertal periods, and with a peak typically located in mid-adolescence, on average around 15 years of age in girls and about one year later in boys. This “acceleration” does not depend only on increased hypothalamic pulses, but also on modulation exerted by sex steroids, which influence peak amplitude, daytime and nighttime distribution and target-tissue sensitivity. Puberty makes a fundamental principle evident: GH physiology cannot be separated from the broader neuroendocrine context, because gonads, energy status, sleep and peripheral signals all contribute to determining how much somatotropic information is actually transmitted to tissues.
In adulthood, the somatotropic system maintains pulsatility, but tends to stabilize on an equilibrium in which information is mainly “pulsed”, with long intervals of very low concentrations interrupted by episodic secretions. A particularly reproducible physiological feature is the association between sleep and secretion: in many individuals, the most constant burst is linked to sleep onset and the emergence of slow-wave sleep, whereas in women the profile may show greater daytime fragmentation with more frequent episodes. Burst amplitude and frequency remain sensitive to factors such as exercise, stress, caloric restriction, inflammatory status and body composition, but the overall logic remains that of a temporal signal rather than a static level. Consequently, intraindividual variability can be very high when single non-standardized samples are observed over time, even in the presence of a personal physiological “signature” observable with repeated and comparable measurements.
A peculiar chapter of reproductive life is pregnancy, in which maternal GH physiology changes qualitatively: pituitary secretion tends to decrease while the placental component progressively increases (placental GH, GH-V variant), becoming a relevant proportion of circulating immunoreactive GH and contributing to maternal metabolic adaptation and the IGF-1 profile. This aspect is important because it introduces a specific biological and analytical variable: the presence of GH-like molecules with high homology may influence GH measurement in a method-dependent way, making pregnancy an example in which “life physiology” and “physics of measurement” are tightly intertwined.
With aging, a progressive reduction in GH secretion is observed, a phenomenon often described as “somatopause”. The decrease mainly affects burst amplitude rather than frequency, with a decline that becomes evident already after the age of 30 and continues through subsequent decades. In physiological terms, the central point is that the somatotropic axis of the older person is not simply a “weaker” version of that of the young adult, but a remodeled system: lean mass, adipose compartment, sleep quality, physical activity and sensitivity to metabolic signals all change, and each of these factors feeds back on secretory dynamics. The result is a picture in which mean GH is lower and the temporal profile may be more vulnerable to perturbations, with biological variability tending to increase in the presence of comorbidities and changes in the sleep-wake rhythm.
Overall, GH follows a physiological trajectory that starts from high adaptive levels in the newborn, organizes into a growth-oriented system in the child, reaches a functional maximum in puberty, maintains highly context-dependent pulsatile regulation in adulthood and remodels with progressive reduction in older age. This natural history imposes a conceptual conclusion: discussing GH without considering age and biological status means ignoring a substantial part of its physiology.
GH measurement is mainly based on immunoassays, currently largely in two-site immunometric (sandwich) format, in which a capture antibody and a detection antibody recognize distinct epitopes of the molecule. This scheme provides high sensitivity and a broad analytical range, but introduces an essential methodological principle: what is quantified is not “GH” as a single entity, but a specific fraction of immunoreactive GH defined by the antibody combination, calibration and architecture of the analytical system. Measurement quality therefore depends on the interaction between antibody affinity, signal chemistry, background-noise management, biological matrix and interference control.
A central element of laboratory principles is standardization. To improve harmonization between platforms, many methods calibrate against international standards of the World Health Organization, particularly the standard for recombinant somatropin, for example WHO IS 98/574. This step has reduced part of the variability historically observed between methods, but it does not eliminate residual differences because calibration, however traceable, does not ensure full commutability between reference material and native human serum under all analytical conditions. In other words, a standard may behave slightly differently from real circulating GH, which is a set of isoforms and modified forms immersed in a complex matrix of proteins and potential interferents.
The deeper reason for this imperfect commutability lies in the molecular heterogeneity of GH. The predominant form is 22 kDa, but isoforms generated by alternative splicing exist, such as the 20 kDa form, along with post-translational variants, proteolytic fragments and oligomeric forms. From an immunometric standpoint, each of these forms may have different reactivity depending on the selected epitopes, producing signal differences between platforms even when the overall bioactivity of the sample is similar. This leads to an often underestimated practical principle: the reported value is partly method-dependent, and comparability over time requires attention, especially when moving from one analytical system to another.
A further level of complexity is represented by GH binding protein (GHBP), derived from the GH receptor and present in the circulation. Although it is not an “interference” in the strict sense, its presence contributes to GH dynamics in the sample and may variably influence epitope accessibility depending on test conditions and antibody design. This aspect recalls that the immunoassay is a chemical model in which availability of the target for antibody binding is part of the equation, not a guaranteed assumption.
The preanalytical phase is particularly critical for GH because secretion is pulsatile and strongly modulated by context. Sampling time, relationship with sleep, recent physical exercise, acute stress, caloric intake and fasting conditions may substantially modify the observed concentration even in physiologically stable individuals. These factors add to classical laboratory variables: matrix type (serum or plasma), centrifugation timing, stability at room temperature and under refrigeration, and effects of freeze-thaw cycles. In longitudinal comparisons, standardization of the preanalytical context is an integral part of the “laboratory principle”, because it reduces a relevant share of variability unrelated to the analytical system.
A specific chapter concerns physiological conditions in which the composition of immunoreactive GH changes. Pregnancy is the best-known example: the increase in GH of placental origin and the presence of molecules highly homologous to pituitary GH and to human placental lactogen (hPL) may generate spurious signals or, in some systems, negative or positive interferences depending on the interaction with the antibodies used. It follows that accuracy is not an absolute property of the method, but its ability to correctly measure the target in the specific biological context of the sample.
Interferences in immunochemical methods are another pillar of laboratory principles. Heterophile antibodies, anti-species antibodies, anti-reagent antibodies and, in subjects exposed to therapeutic proteins, anti-GH antibodies may alter formation of the immunometric complex and produce falsely elevated or falsely reduced results. A particular phenomenon, although rare, is the presence of macrocomplexes, such as macro-GH, in which GH forms complexes with immunoglobulins, modifying clearance and reactivity in the test and causing discrepancies between methods. The high-dose effect, with saturation of sandwich components and signal distortion, may also occur in some analytical designs and should be considered an intrinsic limit of binding kinetics when the system is pushed outside its linearity range.
A cross-cutting interference of major modern relevance is biotin in systems using the biotin-streptavidin pair. In this context, excess free biotin in the sample can prevent anchoring of the complex to the solid phase or alter separation steps, generating artifactual results whose direction depends on the immunoassay architecture. The conceptual point is that, even when the target is present, the measurement may fail because the chemical chain that translates binding into signal is perturbed.
Finally, alternative or complementary approaches to immunoassays should be remembered, including mass spectrometry-based methods for selected isoforms and in vitro bioactivity systems, but their routine application is more limited than immunometry. This plurality of approaches clarifies a general conclusion: GH measurement is a highly complex laboratory measurement, in which standardization, molecular heterogeneity, preanalytics and interferences jointly determine the meaning of the reported number.
GH is often imagined as a measurable quantity that “represents” an individual’s somatotropic status, but physiology requires a different interpretation: circulating GH is a temporal and contextual signal, not a static level. Its secretion occurs in intermittent bursts separated by very long periods of low concentrations, and the informative content resides in the frequency, amplitude and timing of peaks in relation to sleep, nutrition and stress. A single value, by definition, samples a random point of a highly discontinuous curve and therefore cannot capture the structure of biological information contained in the secretory profile.
A first conceptual limit is therefore pulsatility combined with the brief persistence of the signal: GH has relatively rapid kinetics and a short half-life compared with many other hormones, so the concentration can change markedly over short periods even under stable physiological conditions. This makes GH an extreme case of a “time-dependent biomarker”, but not in a simply circadian sense: the problem is not only the time of day, but the position of the sample in relation to an episodic secretory event, often unobservable without serial sampling.
A second limit is its high dependence on non-pathological physiological determinants. The secretory profile responds sensitively to exercise, hypoglycemia, fasting, protein intake, sleep quality and stressors. Body composition also importantly modulates secretion and clearance, and differences related to biological sex, pubertal phase and estrogen status influence burst amplitude and distribution. As a result, two physiological subjects may have very different profiles despite comparable health status, and the same subject may show substantial variations if the context in which the signal is generated changes.
A third limit concerns the distinction between “measured GH” and “somatotropic effect”. Many GH actions are mediated by IGF-1, but a relevant proportion is also IGF-independent, and the final effect depends on receptor availability, competence of intracellular transduction and the presence of negative pathway modulators, for example systems that attenuate JAK2-STAT5. This means that the same circulating concentration may produce different effects in different tissues or under different conditions of receptor sensitivity, and that an isolated value does not allow inference of the intensity of downstream biological action, which is the product of signal, receptor, transduction and metabolic context.
A fourth conceptual limit is the molecular heterogeneity of GH. Because isoforms and modified forms coexist in the circulation, and because immunoassays “see” GH through selected epitopes, the reported number does not necessarily represent the sum of all forms with identical weighting. This is an epistemological limit: the GH value is not an absolute property of the sample, but the output of a measurement system. In the presence of variations in isoform profile, complexation with immunoglobulins or chemical interferences, the number may diverge from the real amount of free monomeric GH or from overall bioactivity.
A fifth limit, often overlooked, is that GH is a signal that “lives” across multiple compartments and times. The peripheral response involves gene transcription, protein synthesis, variations in substrate availability and adaptations that have slower time constants than plasma bursts. Consequently, the system may frequently be in transitional states: the sample may reflect a moment of adjustment between hypothalamic stimuli, somatostatinergic modulation and peripheral feedback, without this corresponding to a new stable equilibrium. A single isolated value does not distinguish between equilibrium and transition.
Finally, there is a conceptual limit related to the plurality of “surrogates” of the somatotropic signal. IGF-1 and other components of the IGF system, together with binding proteins, represent signals more integrated over longer time scales and with lower intradiel variability, whereas GH is a high-frequency, high-variability signal. This does not make GH less physiological, but it clarifies that no single indicator can summarize an axis that encodes information across multiple times, multiple molecules and multiple levels of regulation. GH, taken in isolation, is therefore an excellent example of a biomarker that requires context in order to be “information”, because without context it remains only a point sample of a dynamic phenomenon.